Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Board Appointment for IPO-ready Dimension Therapeutics

Just days after setting the terms for its pending IPO, Dimension Therapeutics, Inc., a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders,  announced the election of Alan B. Colowick, M.D., M.P.H., Executive Vice President of Celgene Corporation, to Dimension’s Board of Directors. Dr. Colowick brings strong operational expertise and more than 15 years of experience in biopharmaceutical development. His election to the company’s Board is effective immediately.

“Alan has a successful and highly regarded career in the life sciences, and we are pleased to welcome him to Dimension’s Board,” said Annalisa Jenkins, MBBS, MRCP, Chief Executive Officer of Dimension. “His track record in advancing products into the market and successfully commercializing them will be vital as we continue to progress our lead programs for rare, genetic diseases associated with the liver, including our wholly owned program in hemophilia B, which is anticipated to enter the clinic this year.”

Prior to his current role as Executive Vice President of Celgene Corporation, Dr. Colowick was Celgene’s President of the Europe, Mid-East, and Africa region (EMEA), for which he was responsible for staff and operations in over 40 countries, and prior to that served as Senior Vice President, Global Medical Affairs. Previously, he was Chief Executive Officer of Gloucester Pharmaceuticals, LLC (acquired by Celgene in 2010), and prior to this, he was President, Oncology at Geron Corporation. He also served as Chief Medical Officer of Threshold Pharmaceuticals, and prior to this, Dr. Colowick held leadership positions of increasing responsibility at Amgen Inc., including as Vice President of European Medical Affairs. While at Amgen, Dr. Colowick led the team responsible for the successful registration and launch of Aranesp® in the US, EU, and Australia. He holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University, and an M.P.H. from Harvard University. Dr. Colowick also completed a clinical and research fellowship in hematology and oncology at the Dana Farber Cancer Institute and Brigham and Women’s Hospital at Harvard University.

Join our event on gender diversity in biotech on December 3rd 2015 in Cambridge, MA.

Posted in Board Director Appointments | Tagged , , , , , , , , , , , | Leave a comment

Contact Us

   Head Office
Liftstream Ltd.
111 Buckingham Palace Road,
   Tel: ​+44 (0)20 3180 5880

Register your CV

Apply for sector specific vacancies or request a confidential discussion

Registered in England No: 5009233
VAT: 843679292

Follow Us